



# CRISPR/Cas9 as ONE tool to improve animal models


Mark Johnson, PhD

Associate Director, Product Development  
Scientific Services  
Taconic Biosciences

January 9, 2024

# Applications for Genetically Engineered Animal Models in Infectious Disease and Vaccine Research


## Conferring Infectivity / Susceptibility



Min L, Sun Q. Antibodies and Vaccines Target RBD of SARS-CoV-2. *Front Mol Biosci.* 2021 Apr 22;8:671633. doi: 10.3389/fmolb.2021.671633. Licensed under CC BY 4.0 (<https://creativecommons.org/licenses/by/4.0/>).

- Humanization of surface proteins necessary for viral entry
- Introduction of human genetic elements that facilitate or enhance infection by pathogens
- Models used for infection studies and measuring efficacy of vaccine therapeutics


## Humanized Antigen Presentation



- Mice expressing human MHCs (HLAs)
- Transgenes confer human-like presentation of antigens
- Mouse/Human chimeric HLAs facilitate T-cell responses
- Widely used for vaccine development


# Applications for Genetically Engineered Animal Models in Infectious Disease and Vaccine Research

## Humanized Immune System Platforms




- Genetic inactivation of mouse immune system
- Humanization of cytokines and immune factors supporting development of specific hematopoietic lineages
- Engraftment of human immune progenitor cells
- Examples: NSG mice from Jackson Labs, NOG mice from Taconic

## Humanized Antibody Platforms



- Introduction of engineered transgenes encoding human immunoglobulin repertoires, V(D)J and/or C segments.
- Some platforms retain mouse constant domains and generate human/mouse chimeric antibodies
- Examples: Trianni Mouse, OmniMouse, AlivaMab Mouse

# Genome Engineering Technologies for Model Generation in Rodents



	Random Integration Transgenesis	Gene Targeting in ES Cells	CRISPR/Cas9 Gene Editing
Targeting Method	Zygote Pronuclear Injection	ES Cell Electroporation	Zygote Pronuclear Injection or Electroporation
Type of Integration	Random	Targeted	Targeted
Species	Any <sup>1</sup>	Mouse	Any <sup>1, 2</sup>
Mouse Genetic Backgrounds	Any <sup>1</sup>	Only for strains with established ES cells	Any <sup>1, 2</sup>
Level of Precision	Low	High	Medium, Increasing
Maximum Size of Insertion	≤ 250 kb (BAC)	≤ 180 kb	≤ 5 kb, Increasing
Model Generation Time	≥ 9 months	≥ 12 months	≥ 6 months
Time to First Cohort	≥ 15 months	≥ 18 months	≥ 12 months


<sup>1</sup> any from which zygotes can be harvested and manipulated

<sup>2</sup> any where genome sequencing data is available

# Example of CRISPR/Cas9 Advantages for Model Development


## Precision, Speed, Accessibility

Random Integration Transgenic Humanized ACE2 Model  
Expressing full length human ACE2 driven by exogenous promoter



- Infection causes complete lethality
- Unknown location of transgene
- Unknown transgene copy number
- Unpredictable tissue distribution
- Relied on chance of a suitable allele
- Required backcrossing


CRISPR/Cas9 Point-Mutation Humanized ACE2 Model  
Expressing mouse *Ace2* from endogenous locus with humanization of only amino acid H353



- H353K confers SARS-CoV-2 infectivity in mice
- Receptor stoichiometry is maintained
- Receptor retains endogenous signaling
- Receptor is expressed where expected
- No backcrossing necessary
- Precision editing, but 6 months faster than ES cell approach
- Translatable to other strains and species

# Preparedness: Tactics for Rapid & Efficient Model Development

Create generalized work plans for model development suited for specific classes of pathogens



Apply state-of-the art technologies and industry tricks

# Preparedness: Community-Driven Model Repositories

Reproductive Lifecycle is FIXED. Even with CRISPR/Cas9, the shortest amount of time it takes to generate a *de novo* mouse model and obtain a first experimental cohort is still **~ 1 YEAR**


Anticipate need →

Generate animal models **NOW** and **cryobank** genetic lines

Public Health Organizations  
& Disease Foundations




Model Generation Cores &  
Commercial Model Providers



Cryopreserved Models

## Expand Repertoire of HLA-expressing Models

- Create transgenic models for the remaining human HLAs
- Map and characterize HLA transgenes and/or
- Create knock-in versions targeted to safe-harbor loci
- Create engineered transgene(s) encoding full set of HLA



An HLA gene region of Human Chr. 6

Created with BioRender.com

## Create Model Collections for Pathogen Classes

- Humanize common receptors for viral classes
- Introduce susceptibility factors for classes of pathogens or related to human populations
- Create new models on genetic backgrounds permissive to studying infectious diseases

## Clear the path for rapid recovery and distribution

- Create cryorecovery and colony expansion plans
- Anticipate and clear regulatory hurdles to international shipment and global distribution
- Design legal terms to be permissive to sharing with research community



🏛️ Expertise

★ Superior Products

🌐 Unique Platforms

**Thank you for your attention.**

Mark Johnson, PhD  
Mark.Johnson@taconic.com

